Elfabrio®

Understanding Elfabrio®

Elfabrio® (pegunigalsidase alfa-iwxj) is an enzyme replacement therapy designed for adults with confirmed Fabry disease. This therapy supplements the deficient alpha-galactosidase A enzyme, aiding in the breakdown of globotriaosylceramide (Gb3) deposits that accumulate in tissues such as the kidneys, heart, and nervous system.

How Elfabrio® Works:

• Enzyme Replacement: Provides the missing alpha-galactosidase A enzyme, facilitating the breakdown of harmful Gb3 deposits.

• Disease Management: Aims to reduce the progression of Fabry disease by addressing the underlying enzyme deficiency.

• Regular Infusions: Administered intravenously every two weeks under the supervision of a healthcare professional.

FDA Approval:

• Elfabrio® was approved by the U.S. Food and Drug Administration (FDA) on May 9, 2023, for the treatment of adult patients with confirmed Fabry disease.

For more information, please visit the Elfabrio® patient website and consult your healthcare provider to determine if Elfabrio® is the right treatment option for you.